.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a median consequence of 11 months, clients with metastatic stomach lumps who obtained biomarker-matched treatments based on distributing growth DNA profiling presented a higher scientific benefit than those getting incomparable therapy.